Aclaris Therapeutics, Inc.
ACRS
$1.57
$0.063.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.96% | -6,375.65% | 74.07% | 62.85% | 39.84% |
| Total Depreciation and Amortization | -47.33% | -37.28% | -18.26% | 11.01% | 22.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.56% | 571.26% | -50.26% | -38.21% | -18.60% |
| Change in Net Operating Assets | 78.51% | -107.49% | 909.45% | -227.37% | -104.82% |
| Cash from Operations | 37.27% | -32.20% | 189.59% | 40.34% | 21.01% |
| Capital Expenditure | 68.15% | 100.00% | 100.00% | 106.06% | 75.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.93% | -1,210.29% | -91.43% | 96.46% | -35.61% |
| Cash from Investing | 13.58% | -1,275.14% | -91.41% | 96.57% | -34.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 9,042.86% | 113.33% | -- | -- |
| Repurchase of Common Stock | -400.00% | -- | 90.20% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -515.86% | -- | -- | -- |
| Cash from Financing | -400.00% | 152,104.08% | 125.29% | -100.04% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 243.35% | -2,854.30% | 214.54% | 4.16% | -627.39% |